Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Renal Cell 27Neoplasms 9Kidney Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Carcinoma 7Lung Neoplasms 4Carcinoma, Hepatocellular 4Neoplasm Metastasis 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Solid Tumors 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Melanoma 2Kidney Diseases 2Advanced Solid Tumors 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Liver Diseases 1Leukemia, Myeloid, Acute 1Glioblastoma 1

Interventions

Temozolomide 94Radiotherapy 40Bevacizumab 40Lomustine 21Radiation 18Surgical Procedures, Operative 10Carboplatin 9pembrolizumab 8Nivolumab 8Carmustine 8Irinotecan 7IL13-PE38 6Granulocyte-Macrophage Colony-Stimulating Factor 6Flucytosine 6Cyclophosphamide 6ABT-414 6vocimagene amiretrorepvec 5depatuxizumab mafodotin 5Valacyclovir 5Drug Therapy 5veledimex 4sargramostim 4enzastaurin 4NVP-BKM120 4Gemcitabine 4Dianhydrogalactitol 4Chlorotoxin 4Aminolevulinic Acid 4verubulin 3selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioblastoma × Axitinib × Clear all
NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡